Faron Pharmaceuticals Oy (FRA:4FR) Marketable Securities: €0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4FR Faron Pharmaceuticals Oy FRA:4FR
28 GF Score
Price €0.48
! 4 Warning Signs
View Full Analysis

What is Faron Pharmaceuticals Oy Marketable Securities?

Faron Pharmaceuticals Oy FRA:4FR -0.62% 28 Marketable Securities is €0.00 Mil as of Dec. 2025. GuruFocus rates FRA:4FR with a GF Score™ of 28/100. The stock has 4 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Faron Pharmaceuticals Oy's Marketable Securities for the quarter that ended in Dec. 2025 was €0.00 Mil.

Faron Pharmaceuticals Oy  (FRA:4FR) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Faron Pharmaceuticals Oy Marketable Securities Related Terms

Faron Pharmaceuticals Oy Marketable Securities Historical Data

* Premium members only.

The historical data trend for Faron Pharmaceuticals Oy's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Faron Pharmaceuticals Oy Marketable Securities Chart

Faron Pharmaceuticals Oy Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Faron Pharmaceuticals Oy Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:4FR
28GF Score
Faron Pharmaceuticals Oy FRA:4FR
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Faron Pharmaceuticals Oy Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of €0.00 Mil mean?
Faron Pharmaceuticals Oy (FRA:4FR) has a Marketable Securities of €0.00 Mil as of Dec. 2025. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Faron Pharmaceuticals Oy and its competitors.
Is Faron Pharmaceuticals Oy's Marketable Securities too high?
Faron Pharmaceuticals Oy's current Marketable Securities is €0.00 Mil. Overall, Faron Pharmaceuticals Oy has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Faron Pharmaceuticals Oy's Marketable Securities compare to VRTX and REGN?
Faron Pharmaceuticals Oy's Marketable Securities of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Faron Pharmaceuticals Oy and its competitors. Faron Pharmaceuticals Oy's current Marketable Securities is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Faron Pharmaceuticals Oy stock overvalued right now?
Faron Pharmaceuticals Oy (FRA:4FR) has a current Marketable Securities of €0.00 Mil. The current Marketable Securities is €0.00 Mil. Faron Pharmaceuticals Oy's overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Faron Pharmaceuticals Oy (FRA:4FR), the current Marketable Securities is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Faron Pharmaceuticals Oy Business Description

Other Exchanges FARN:UKFARON:Finland
Address Joukahaisenkatu 6 B, Turku, FIN, 20520
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company. The company has one operating and reportable segment. The Group has a pipeline based on the receptors involved in the regulation of immune response in oncology, organ damage, and bone marrow regeneration. Faron is a late clinical stage drug discovery and development Group. The company includes Bexmarilimab in its pipeline. Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and improve clinical outcomes by targeting myeloid cell function in the microenvironment and igniting the immune system against cancer.
28GF Score

Get the complete analysis for FRA:4FR

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.48
Price